1
|
Zolotarev YA, Shram SI, Dadayan AK, Dolotov OV, Markov DD, Nagaev IY, Kudrin VS, Narkevich VB, Sokolov OY, Kost NV. HLDF-6 peptides exhibit neuroprotective effects in the experimental model of preclinical Parkinson's disease. Neuropeptides 2022; 96:102287. [PMID: 36280440 DOI: 10.1016/j.npep.2022.102287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Revised: 09/05/2022] [Accepted: 09/10/2022] [Indexed: 10/14/2022]
Abstract
The mechanisms of the neuroprotective action of the hexapeptides HLDF-6 encoded by the amino acid sequence 41-46 of Human Leukemia Differentiation Factor and its homoserine derivative HLDF-6H were studied in an experimental 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model of Parkinson's disease (PD). C57Bl/6 mice received two intraperitoneal injections of 18 mg/kg MPTP-HCl, with an interval of 2 hours. MPTP-induced motor dysfunction was assessed using horizontal grid test. Our data show that chronic intranasal administration of peptides (3 weeks, 300 μg/kg/day) restored normal levels of dopamine and improved its turnover rates in the striatum. Furthermore, peptide administration increased serum estradiol levels and led to a significant improvement in motor functions in MPTP-treated mice. Additionally, peptide treatment increased the levels of mRNA encoding neurotrophin BDNF, but normalized the levels of mRNA encoding the inflammatory mediators TGFβ1, IL1β and IFNγ in the brain. Collectively, our behavioral and biochemical studies demonstrate that HLDF-6 peptides have a therapeutic potential for treating PD. We propose that HLDF-6 peptides may exert their neuroprotective mechanism, at least in part, by normalizing estradiol levels and modulating the expression of key factors involved in neurotrophic support and neuroinflammation.
Collapse
Affiliation(s)
- Yurii A Zolotarev
- Institute of Molecular Genetics of National Research Center «Kurchatov Institute», Moscow, Russia.
| | - Stanislav I Shram
- Institute of Molecular Genetics of National Research Center «Kurchatov Institute», Moscow, Russia
| | - Aleksandr K Dadayan
- Institute of Molecular Genetics of National Research Center «Kurchatov Institute», Moscow, Russia
| | - Oleg V Dolotov
- Institute of Molecular Genetics of National Research Center «Kurchatov Institute», Moscow, Russia; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
| | - Dmitriy D Markov
- Institute of Molecular Genetics of National Research Center «Kurchatov Institute», Moscow, Russia
| | - Igor Yu Nagaev
- Institute of Molecular Genetics of National Research Center «Kurchatov Institute», Moscow, Russia
| | | | | | | | | |
Collapse
|
2
|
Zolotarev YA, Mitkevich VA, Shram SI, Adzhubei AA, Tolstova AP, Talibov OB, Dadayan AK, Myasoyedov NF, Makarov AA, Kozin SA. Pharmacokinetics and Molecular Modeling Indicate nAChRα4-Derived Peptide HAEE Goes through the Blood-Brain Barrier. Biomolecules 2021; 11:biom11060909. [PMID: 34207317 PMCID: PMC8234734 DOI: 10.3390/biom11060909] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 06/14/2021] [Accepted: 06/15/2021] [Indexed: 12/24/2022] Open
Abstract
One of the treatment strategies for Alzheimer's disease (AD) is based on the use of pharmacological agents capable of binding to beta-amyloid (Aβ) and blocking its aggregation in the brain. Previously, we found that intravenous administration of the synthetic tetrapeptide Acetyl-His-Ala-Glu-Glu-Amide (HAEE), which is an analogue of the 35-38 region of the α4 subunit of α4β2 nicotinic acetylcholine receptor and specifically binds to the 11-14 site of Aβ, reduced the development of cerebral amyloidogenesis in a mouse model of AD. In the current study on three types of laboratory animals, we determined the biodistribution and tissue localization patterns of HAEE peptide after single intravenous bolus administration. The pharmacokinetic parameters of HAEE were established using uniformly tritium-labeled HAEE. Pharmacokinetic data provided evidence that HAEE goes through the blood-brain barrier. Based on molecular modeling, a role of LRP1 in receptor-mediated transcytosis of HAEE was proposed. Altogether, the results obtained indicate that the anti-amyloid effect of HAEE, previously found in a mouse model of AD, most likely occurs due to its interaction with Aβ species directly in the brain.
Collapse
Affiliation(s)
- Yurii A. Zolotarev
- Laboratory of Protein Conformational Polymorphism in Health and Disease, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia; (Y.A.Z.); (V.A.M.); (A.A.A.); (A.P.T.); (A.A.M.)
- Department of Physiologically Active Substances Chemistry, Institute of Molecular Genetics of National Research Center «Kurchatov Institute», 123182 Moscow, Russia; (S.I.S.); (A.K.D.); (N.F.M.)
| | - Vladimir A. Mitkevich
- Laboratory of Protein Conformational Polymorphism in Health and Disease, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia; (Y.A.Z.); (V.A.M.); (A.A.A.); (A.P.T.); (A.A.M.)
| | - Stanislav I. Shram
- Department of Physiologically Active Substances Chemistry, Institute of Molecular Genetics of National Research Center «Kurchatov Institute», 123182 Moscow, Russia; (S.I.S.); (A.K.D.); (N.F.M.)
| | - Alexei A. Adzhubei
- Laboratory of Protein Conformational Polymorphism in Health and Disease, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia; (Y.A.Z.); (V.A.M.); (A.A.A.); (A.P.T.); (A.A.M.)
| | - Anna P. Tolstova
- Laboratory of Protein Conformational Polymorphism in Health and Disease, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia; (Y.A.Z.); (V.A.M.); (A.A.A.); (A.P.T.); (A.A.M.)
| | - Oleg B. Talibov
- Department of Clinical Pharmacology, Faculty of Common Medicine, Evdokimov Moscow State University of Medicine and Dentistry, 127473 Moscow, Russia;
| | - Alexander K. Dadayan
- Department of Physiologically Active Substances Chemistry, Institute of Molecular Genetics of National Research Center «Kurchatov Institute», 123182 Moscow, Russia; (S.I.S.); (A.K.D.); (N.F.M.)
| | - Nikolai F. Myasoyedov
- Department of Physiologically Active Substances Chemistry, Institute of Molecular Genetics of National Research Center «Kurchatov Institute», 123182 Moscow, Russia; (S.I.S.); (A.K.D.); (N.F.M.)
| | - Alexander A. Makarov
- Laboratory of Protein Conformational Polymorphism in Health and Disease, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia; (Y.A.Z.); (V.A.M.); (A.A.A.); (A.P.T.); (A.A.M.)
| | - Sergey A. Kozin
- Laboratory of Protein Conformational Polymorphism in Health and Disease, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia; (Y.A.Z.); (V.A.M.); (A.A.A.); (A.P.T.); (A.A.M.)
- Correspondence: ; Tel.: +7-499-135-98-24
| |
Collapse
|
3
|
Kovalev GI, Vasileva EV, Salimov RM, Zolotarev YA, Dadayan AK, Bogachouk AP, Lipkin VM. Influence of Subchronic Administration of the HLDF-6 Peptide on an Efficacy of the Exploratory Behavior of Inbred Mice of the Balb/c and C57Bl/6 Strains. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2021. [DOI: 10.1134/s1068162021010118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
4
|
Sokolov OY, Pozdnyakova AN, Cheremnykh EG, Vasileva EV, Kost NV, Zolotarev YA. HLDF-6-Amide Reduces the Cytotoxicity of Doxorubicin and Activates the Proliferation of Tetrahymena pyriformis. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2020. [DOI: 10.1134/s1068162020060321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
5
|
Zolotarev YA, Dadayan AK, Kozik VS, Shram SI, Azev VN, Bogachouk AP, Lipkin VM, Myasoedov NF. Pharmacokinetics of HLDF-6-AA Peptide in the Organism of Experimental Animals. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2020. [DOI: 10.1134/s1068162019050145] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
6
|
Zolotarev YA, Dadayan AK, Kozik VS, Shram SI, Nagaev IY, Azev VN, Bogachouk AP, Lipkin VM, Myasoedov NF. Proteolytic Hydrolysis of the Antitumor Peptide HLDF-6-AA in Blood Plasma. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2019. [DOI: 10.1134/s1068162019050133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
7
|
Sidorova MV, Palkeeva ME, Azmuko AA, Ovchinnikov MV, Molokoedov AS, Bushuev VN, Pisarenko OI. Optimization of the Synthesis of an Apelin-12 Structural Analog and the NMR Study of Its Stability in Human Plasma. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2019. [DOI: 10.1134/s106816201901014x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
8
|
Zolotarev YA, Kovalev GI, Kost NV, Voevodina ME, Sokolov OY, Dadayan AK, Kondrakhin EA, Vasileva EV, Bogachuk AP, Azev VN, Lipkin VM, Myasoedov NF. Anxiolytic activity of the neuroprotective peptide HLDF-6 and its effects on brain neurotransmitter systems in BALB/c and C57BL/6 mice. J Psychopharmacol 2016; 30:922-35. [PMID: 27464742 DOI: 10.1177/0269881116660705] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
This study is focused on a new amide derivative of the peptide HLDF-6 (Thr-Gly-Glu-Asn-His-Arg). This hexapeptide is a fragment of Human Leukaemia Differentiation Factor (HLDF). It displays a broad range of nootropic and neuroprotective activities. We showed, for the first time, that the peptide HLDF-6-amide has high anxiolytic activity. We used 'open field' and 'elevated plus maze' tests to demonstrate anxiolytic effects of HLDF-6-amide (0.1 and 0.3 mg/kg intranasally), which were comparable to those of the reference drug diazepam (0.5 mg/kg). Five daily equipotent doses of HLDF-6-amide selectively mitigated anxiety and increased the density of NMDA receptors in the hippocampus of stress-susceptible BALB/c mice, and had no effect on stress-resilient C57BL/6 mice. The subchronic administration of HLDF-6-amide showed no effect on the density of GABAA and nicotine receptors but was accompanied by a nonselective decrease of the 5-HT2A serotonin receptor density in frontal cortex of both strains. The mechanism of the specific anxiolytic activity of HLDF-6-amide may include its action on the NMDA-glutamatergic receptor system of the hippocampus and on serotonin 5-HT2A-receptors in the prefrontal cortex. The psychotropic activity of HLDF-6-amide is promising for its introduction to medical practice as a highly effective anxiolytic medicine for mental and neurological diseases.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Anna P Bogachuk
- Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia
| | - Vyacheslav N Azev
- Branch of Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, RAS, Pushchino, Moscow Region, Russia
| | - Valery M Lipkin
- Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia
| | | |
Collapse
|